Turn Therapeutics (NASDAQ:TTRX) Upgraded at Wall Street Zen

Wall Street Zen upgraded shares of Turn Therapeutics (NASDAQ:TTRX) from a sell rating to a hold rating in a report issued on Sunday morning,Wall Street Zen reports.

A number of other analysts have also weighed in on TTRX. Weiss Ratings lowered shares of Turn Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Tuesday, August 18th. LADENBURG THALM/SH SH raised shares of Turn Therapeutics to a “strong-buy” rating in a research report on Monday, July 20th. Finally, Zacks Research upgraded shares of Turn Therapeutics to a “hold” rating in a report on Tuesday, July 21st. One investment analyst has rated the stock with a Strong Buy rating, one has given a Buy rating, one has given a Hold rating and two have assigned a Sell rating to the company. According to data from MarketBeat, the company currently has an average rating of “Hold” and a consensus target price of $9.00.

Turn Therapeutics Stock Up 0.1%

Shares of NASDAQ TTRX opened at $13.46 on Friday. Turn Therapeutics has a 52-week low of $2.57 and a 52-week high of $26.50. The firm has a market capitalization of $400.97 million and a price-to-earnings ratio of -46.41. The stock has a 50 day moving average price of $9.90 and a 200 day moving average price of $6.42. The company has a debt-to-equity ratio of 8.83, a quick ratio of 1.19 and a current ratio of 1.19.

Turn Therapeutics (NASDAQ:TTRX) last issued its earnings results on Wednesday, August 12th. The company reported ($0.20) earnings per share for the quarter. Sell-side analysts expect that Turn Therapeutics will post -0.4 earnings per share for the current year.

Hedge Funds Weigh In On Turn Therapeutics

Large investors have recently added to or reduced their stakes in the company. Bank of America Corp DE purchased a new stake in Turn Therapeutics during the second quarter valued at approximately $103,000. Tamar Securities LLC purchased a new position in Turn Therapeutics in the fourth quarter worth $59,000. Jefferies Financial Group Inc. acquired a new position in shares of Turn Therapeutics during the second quarter worth $119,000. DDFG Inc increased its position in shares of Turn Therapeutics by 34.9% during the first quarter. DDFG Inc now owns 70,534 shares of the company’s stock worth $226,000 after purchasing an additional 18,246 shares in the last quarter. Finally, Bridgewater Advisors Inc. purchased a new stake in Turn Therapeutics in the second quarter valued at about $242,000.

Turn Therapeutics Company Profile

We are a pharmaceutical and medical device development company built around a proprietary platform technology designed to enhance drug performance. Our patented mixing process — commercially referred to as PermaFusion™ (“PermaFusion”) — enables stable suspension of polar, water-soluble active pharmaceutical ingredients (“APIs”) in oil-based carriers without the use of emulsifiers. This innovation reduces the quantity of required API inclusion by improving its bioavailability. Reduced API load reduces the likelihood of adverse events.